GlassScriptPhysician profile
Georgia S Stephenson
NPI 1528066172
$3,092.38
in general payments reported to CMS, 2019-2025
20 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $412 · 2021: $183 · 2022: $1,020 · 2023: $446 · 2024: $243 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $545.99 | 2019-2025 | Argos, Tryptyr, Rocklatan |
| Biotissue Holdings INC. | $417.77 | 2022-2025 | |
| Rxsight INC | $285.33 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $282.84 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $261.26 | 2019-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $202.19 | 2019-2021 | |
| Allergan, INC. | $157.20 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.07 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $133.21 | 2024-2025 | Xdemvy |
| Akorn, INC. | $132.20 | 2019-2020 | |
| Shire North American Group INC | $121.83 | 2019 | |
| Oyster Point Pharma, INC. | $85.02 | 2022-2024 | Tyrvaya |
| Amgen INC. | $81.70 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $59.98 | 2022-2023 | Dextenza |
| Novartis Pharmaceuticals Corporation | $44.12 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $41.42 | 2021 | |
| Bausch & Lomb Americas INC. | $37.59 | 2022-2023 | Vyzulta |
| Merz Pharmaceuticals, LLC | $36.93 | 2021 | |
| Horizon Therapeutics Plc | $16.49 | 2022 | |
| Thea Pharma INC. | $13.24 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgia Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.